Cargando…

A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention

Dendritic cells (DCs) are potent antigen-presenting cells that play a critical role in activating cellular and humoral immune responses. DC-based tumor vaccines targeting tumor-associated antigens (TAAs) have been extensively tested and demonstrated to be safe and potent in inducing anti-TAA immune...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jie, Liu, Hui, Jehng, Tiffany, Li, Yanqing, Chen, Zhoushi, Lee, Kuan-Der, Shen, Hsieh-Tsung, Jones, Lindsey, Huang, Xue F., Chen, Si-Yi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966557/ https://www.ncbi.nlm.nih.gov/pubmed/31805690 http://dx.doi.org/10.3390/cancers11121909

Ejemplares similares

An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses
por: Wang, Guan, et al.
Publicado: (2020)

Advances in Nanotechnology for Cancer Immunoprevention and Immunotherapy: A Review
por: Koyande, Navami Prabhakar, et al.
Publicado: (2022)

Immunoprevention approaches for cancer prevention
por: Umar, Asad
Publicado: (2014)

Cancer Immunoprevention and Public Health
por: Singh, Sandeep K., et al.
Publicado: (2017)

Costs related to immunopreventable diseases: Brazil and its geographic areas (immunopreventable diseases’ costs in Brazil)
por: da Costa, Élide Sbardellotto M., et al.
Publicado: (2021)

Modelling vaccination schedules for a cancer immunoprevention vaccine
por: Motta, Santo, et al.
Publicado: (2005)

An Overview of Cancer Prevention: Chemoprevention and Immunoprevention
por: Gu, Kyle J., et al.
Publicado: (2020)

Vaccines for immunoprevention of DNA mismatch repair deficient cancers
por: Hernandez-Sanchez, Alejandro, et al.
Publicado: (2022)

Targeted Vaccination against Human α-Lactalbumin for Immunotherapy and Primary Immunoprevention of Triple Negative Breast Cancer
por: Tuohy, Vincent K., et al.
Publicado: (2016)

Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine
por: Pan, Jing, et al.
Publicado: (2017)

Vaccination-Based Immunoprevention of Colorectal Tumors: A Primer for the Clinician
por: Jackson, Katy, et al.
Publicado: (2022)

COVID-19: The Need for Immunoprevention at Industrial Scale
por: Halstead, Scott B.
Publicado: (2020)

Epithelial Mutant p53 Promotes Resistance to Anti-PD-1-Mediated Oral Cancer Immunoprevention in Carcinogen-Induced Mouse Models
por: Wang, Jin, et al.
Publicado: (2021)

Immunotherapy of pediatric brain tumor patients should include an immunoprevention strategy: a medical hypothesis paper
por: Driggers, Lara, et al.
Publicado: (2009)

Cancer immunoprevention: from mice to early clinical trials
por: Palladini, Arianna, et al.
Publicado: (2018)

Lynch syndrome cancer vaccines: A roadmap for the development of precision immunoprevention strategies
por: Sei, Shizuko, et al.
Publicado: (2023)

Immunoprevention of Basal Cell Carcinomas with Recombinant Hedgehog-interacting Protein
por: Vogt, Annika, et al.
Publicado: (2004)

Health Disparities in the Immunoprevention of Human Papillomavirus Infection and Associated Malignancies
por: Bakir, Amira H., et al.
Publicado: (2015)

Hospital costs of immunopreventable diseases in the economically active population in Brazil
por: da Costa, Élide Sbardellotto M., et al.
Publicado: (2021)

Toxoplasma Rhoptries: Unique Secretory Organelles and Source of Promising Vaccine Proteins for Immunoprevention of Toxoplasmosis
por: Dlugonska, Henryka
Publicado: (2008)

Precision and Immunoprevention Strategies for Tobacco-Related Head and Neck Cancer Chemoprevention
por: Centuori, Sara M., et al.
Publicado: (2021)

Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR‐Driven Lung Cancer
por: Huang, Mofei, et al.
Publicado: (2022)

Multidrug Resistance in Cancer: Understanding Molecular Mechanisms, Immunoprevention and Therapeutic Approaches
por: Emran, Talha Bin, et al.
Publicado: (2022)

Cancer Moonshot Immuno-Oncology Translational Network (IOTN): accelerating the clinical translation of basic discoveries for improving immunotherapy and immunoprevention of cancer
por: Annapragada, Ananth, et al.
Publicado: (2020)

CD36-BATF2\MYB Axis Predicts Anti-PD-1 Immunotherapy Response in Gastric Cancer
por: Jiang, Qiuyu, et al.
Publicado: (2023)

Striking efficacy of a vaccine targeting TOP2A for triple-negative breast cancer immunoprevention
por: Lee, Sang Beom, et al.
Publicado: (2023)

Global research trends on anti-PD-1/anti-PD-L1 immunotherapy for triple-negative breast cancer: A scientometric analysis
por: Wu, Jinyao, et al.
Publicado: (2023)

Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy
por: Liu, Hao, et al.
Publicado: (2022)

Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Croci, Stefania, et al.
Publicado: (2015)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review
por: Chen, Ke, et al.
Publicado: (2021)

The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
por: Qu, Jingjing, et al.
Publicado: (2021)

Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
por: García-Aranda, Marilina, et al.
Publicado: (2019)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?
por: Dhodapkar, Madhav V., et al.
Publicado: (2019)

Targeting IL-1β as an immunopreventive and therapeutic modality for K-ras–mutant lung cancer
por: Yuan, Bo, et al.
Publicado: (2022)

Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy
por: Gao, Yang, et al.
Publicado: (2020)

Dysregulated ferroptosis‐related genes indicate potential clinical benefits for anti–PD‐1/PD‐L1 immunotherapy in lung adenocarcinoma
por: Zhou, Min, et al.
Publicado: (2021)

Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy
por: Yuan, Yu, et al.
Publicado: (2021)

CD4(+) T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy
por: Xiao, Minglu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_llbkucolk5e10a1g4efa050t7u